Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, parathyroid hormone (Natpar®) cannot be endorsed for use within NHS Wales for the adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone. |
||
|
||
Medicine details |
||
| Medicine name | parathyroid hormone (Natpar®) | |
| Formulation | 25 micrograms powder and solvent for solution for injection, 50 micrograms powder and solvent for solution for injection, 75 micrograms powder and solvent for solution for injection, 100 micrograms powder and solvent for solution for injection | |
| Reference number | 2380 | |
| Indication | For the adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone. |
|
| Company | Shire Pharmaceuticals Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 07/08/2017 | |
| Date of issue | 08/08/2017 | |